325 related articles for article (PubMed ID: 32279524)
1. Prediction of Immune checkpoint inhibitors benefit from routinely measurable peripheral blood parameters.
Voutsadakis IA
Chin Clin Oncol; 2020 Apr; 9(2):19. PubMed ID: 32279524
[TBL] [Abstract][Full Text] [Related]
2. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
3. Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies.
Hernandez C; Arasanz H; Chocarro L; Bocanegra A; Zuazo M; Fernandez-Hinojal G; Blanco E; Vera R; Escors D; Kochan G
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244396
[TBL] [Abstract][Full Text] [Related]
4. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
Hotta K; Fujimoto N
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32098830
[TBL] [Abstract][Full Text] [Related]
5. Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers.
Li Y; Wang J; Wu L; Li X; Zhang X; Zhang G; Xu S; Sun S; Jiao S
Front Immunol; 2021; 12():649343. PubMed ID: 34163469
[TBL] [Abstract][Full Text] [Related]
6. Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors.
An HJ; Chon HJ; Kim C
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502325
[TBL] [Abstract][Full Text] [Related]
7. [Advances in predictive biomarkers associated with immune checkpoint inhibitors for tumor therapy].
Guo R; Li X; Hao M; Liang Y; Wang L; Yang Z
Sheng Wu Gong Cheng Xue Bao; 2023 Apr; 39(4):1403-1424. PubMed ID: 37154314
[TBL] [Abstract][Full Text] [Related]
8. The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors.
Benitez JC; Recondo G; Rassy E; Mezquita L
Q J Nucl Med Mol Imaging; 2020 Jun; 64(2):162-174. PubMed ID: 32107903
[TBL] [Abstract][Full Text] [Related]
9. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy.
Lee M; Samstein RM; Valero C; Chan TA; Morris LGT
Hum Vaccin Immunother; 2020; 16(1):112-115. PubMed ID: 31361563
[TBL] [Abstract][Full Text] [Related]
10. Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care.
Singh S; Numan A; Agrawal N; Tambuwala MM; Singh V; Kesharwani P
Int Immunopharmacol; 2020 Jun; 83():106417. PubMed ID: 32200155
[TBL] [Abstract][Full Text] [Related]
11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers related to immune checkpoint inhibitors therapy.
Li N; Hou X; Huang S; Tai R; Lei L; Li S; Abuliz A; Wang G; Yang S
Biomed Pharmacother; 2022 Mar; 147():112470. PubMed ID: 35074251
[TBL] [Abstract][Full Text] [Related]
13. Advances in clinical immunotherapy for gastric cancer.
Li K; Zhang A; Li X; Zhang H; Zhao L
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188615. PubMed ID: 34403771
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral Versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One?
Gascón M; Isla D; Cruellas M; Gálvez EM; Lastra R; Ocáriz M; Paño JR; Ramírez A; Sesma A; Torres-Ramón I; Yubero A; Pardo J; Martínez-Lostao L
Cells; 2020 Jun; 9(6):. PubMed ID: 32580514
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.
Perrier A; Didelot A; Laurent-Puig P; Blons H; Garinet S
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708698
[TBL] [Abstract][Full Text] [Related]
16. Understanding Suboptimal Response to Immune Checkpoint Inhibitors.
Zhu M; Zhang H; Pedersen KS; Foster NR; Jaszewski BL; Liu X; Hirdler JB; An Z; Bekaii-Saab TS; Halfdanarson TR; Boland PM; Yan Y; Hubbard JH; Ma WW; Yoon HH; Revzin A; Fernandez-Zapico ME; Overman MJ; McWilliams RR; Dong H
Adv Biol (Weinh); 2023 Apr; 7(4):e2101319. PubMed ID: 35343107
[TBL] [Abstract][Full Text] [Related]
17. How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
Denis M; Duruisseaux M; Brevet M; Dumontet C
Front Immunol; 2020; 11():492. PubMed ID: 32265935
[TBL] [Abstract][Full Text] [Related]
18. [Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].
Tang H; Guan M; Sun Z; Bai CM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Dec; 42(6):825-830. PubMed ID: 33423733
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint blockade and biomarkers of clinical response in non-small cell lung cancer.
Hallqvist A; Rohlin A; Raghavan S
Scand J Immunol; 2020 Dec; 92(6):e12980. PubMed ID: 33015859
[TBL] [Abstract][Full Text] [Related]
20. New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review).
Wang Y; Yang S; Wan L; Ling W; Chen H; Wang J
Int J Oncol; 2023 Jul; 63(1):. PubMed ID: 37326100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]